CROI 2026: 15 i-Base reports from this essential conference
24 April 2026. Related: Conference reports.
CROI 33 (Retrovirus) 2026
CROI 2026: Only three new HIV cases on lenacapavir PrEP: updates from PURPOSE-1 and -2
19 April 2026. Related: Conference reports, HIV prevention and transmission.
CROI 2026: investigational HIV combinations – daily, weekly, 4- and 6-monthly…
15 April 2026. Related: Conference reports, Antiretrovirals.
CROI 2026: Persistence and expansion of the HIV reservoir on long-term ART
14 April 2026. Related: Conference reports, Cure-related research, Basic science and immunology.
CROI 2026: Second course of bNAbs slows viral rebound in RIO study and to lower peak levels
14 April 2026. Related: Conference reports, Cure-related research.
LEAP pre-CROI workshop 2026: recordings and presentations online
30 March 2026. Related: Conference reports, Antiretrovirals.
CROI 2026: GLP-1 weight loss drugs include potential immune benefits in gut tissue
13 March 2026. Related: Conference reports, Weight, diabetes, metabolic complications, Coinfections and complications.
CROI 2026: Australian study of 4CMenB vaccine fails to protect gay men against gonorrhoea
10 March 2026. Related: Conference reports, Coinfections and complications.
CROI 2026: Pritelivir active against drug-resistant herpes in phase 3 study
9 March 2026. Related: Conference reports, Coinfections and complications.
CROI 2026: Community breakfast webinars now online
1 March 2026. Related: Conference reports, Activism & advocacy.
CROI 2026: US activist Peter Staley opens CROI: we must all be activists until the next US administration
27 February 2026. Related: Conference reports, Activism & advocacy.
CROI 2026: Statement in support of science
27 February 2026. Related: Conference reports, Activism & advocacy.
CROI 2026: Once-daily oral BIC/LEN simplifies ART for those on complex combinations
25 February 2026. Related: Conference reports, Antiretrovirals.
CROI 2026: Islatravir PrEP didn’t protect against M184V mutation in macaque study
24 February 2026. Related: Conference reports, HIV prevention and transmission, Drug resistance.
CROI 2026: 11 mg dose selected for once-monthly MK-8527 for phase 3 PrEP studies
24 February 2026. Related: Conference reports, HIV prevention and transmission.
CROI 2026: Continued HIV protection from 2:1:1 PrEP dosing in gay and bisexual men in Paris
24 February 2026. Related: Conference reports, HIV prevention and transmission.
CROI 2026: Overview and research to watch out for
23 February 2026. Related: Conference reports.
CROI 2026: Introduction and main themes
21 February 2026. Related: Conference reports.